Brief: Femasys Begins Fembloc Pivotal Trial Enrollment At UC Davis Medical Center
26/01/2024 13:09
Jan 26 (Reuters) - Femasys Inc FEMY.O :
* FEMASYS INC. BEGINS FEMBLOC PIVOTAL TRIAL ENROLLMENT AT UC
DAVIS
MEDICAL CENTER, A HUB FOR INNOVATION AND GROUNDBREAKING RESEARCH
IN HEALTH CARE FOR WOMEN
Source text for Eikon: ID:nGNX9H5VTz
Further company coverage: FEMY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Femasys
See all newsBrief: Femasys - Files For Resale Of Up To 28,124,997 Shares Of Common Stock - SEC Filing
Brief: Femasys Announces FDA Approval Of Modular Pma Submission Approach For Fembloc
Femasys Inc reports results for the quarter ended June 30 - Earnings Summary
Femasys Inc expected to post a loss of $1.30 a share - Earnings Preview
Femasys Inc expected to post a loss of $1.30 a share - Earnings Preview